Drug Profile
Albumin-bound paclitaxel - NAL Pharma
Alternative Names: NAL 1845Latest Information Update: 15 Jan 2022
Price :
$50
*
At a glance
- Originator NAL Pharma
- Class Antineoplastics; Diterpenes; Paclitaxels; Skin disorder therapies; Small molecules; Taxanes; Vascular disorder therapies
- Mechanism of Action Tubulin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Dec 2019 No recent reports of development identified for clinical-Phase-Unknown development in Cancer in Unknown (Injection)
- 12 Dec 2016 Chemical structure information added
- 29 Nov 2016 Albumin-bound paclitaxel - NAL Pharma is available for licensing as of 29 Nov 2016. http://www.nalpharma.com/licensing.php?id=4&lang=en